Cost-Effectiveness of Simvastatin Plus Ezetimibe for Cardiovascular Prevention in Patients With a History of Acute Coronary Syndrome: Analysis of Results of the IMPROVE-IT Trial

743 WITHDRAWN:Â Novel Treatment Strategies for Secondary Prevention of Cardiovascular Disease: A Systematic Review of Cost-Effectiveness

“…The general characteristics of the included articles organised by treatment strategies are summarised in Table 1. Of the selected studies, ten evaluated ezetimibe [12,13,32,33,35,36,[42][43][44][45], 15 PCSK9 inhibitors [12, 26, 28-30, 33, 37-39, 43-48], five n-3 PUFAs [31,40,[49][50][51], and seven the polypill [27,34,41,[52][53][54][55]. Four out of the 15 studies focusing on PCSK9 inhibitors also reported the ICERs of ezetimibe versus statins, but considering ezetimibe as a comparator [12,33,43,44], and those results have also been included and reported in this review.…”

The Impact of Changes in Population LDL-C Levels on LDL-C Control in Patients After PCI in China: A Retrospective Cohort Study

“…However, in a 5-10 year follow-up model, ezetimibe combined with statin therapy is not a cost-effective alternative, but when the follow-up period is extended to a lifetime, combination therapy becomes a cost-effective treatment. [22] In a Chinese study, LDL-C<1.8 mmol/l was 26.2% and 28.2% in patients using high-intensity and moderate-intensity statins, respectively. [23] Another study showed that 63.8% of acute coronary syndrome patients had LDL-C level greater than 1.80 mmol/L, and 71.5% received highintensity statin therapy.…”

“…Systematic analysis of the Global Burden of Disease Study in 2017 showed that cardiovascular disease remained the leading cause of death worldwide, with 8.9 million deaths from ischemic cardiomyopathy, a 22.3% increase over 2007. [1] China is the world's most populous country, with 290 million people suffering from cardiovascular disease and 5 million patients with coronary artery disease(CAD).…”

<p>Cost-Effectiveness Analysis of Ezetimibe as the Add-on Treatment to Moderate-Dose Rosuvastatin versus High-Dose Rosuvastatin in the Secondary Prevention of Cardiovascular Diseases in China: A Markov Model Analysis</p>

“…Our study was in line with previous studies investigated the cost-effectiveness of ezetimibe combined with statin using different models in different clinical contexts. [35][36][37][38][39][40][41][42][43] de Labry Lima et al 35 that it is cost-effective to treat patients with high cardiovascular risk with ezetimibe plus atorvastatin than switching to rosuvastatin. In particular patients with acute coronary syndrome (ACS) 37,40 or chronic kidney disease (CKD), 41 the cost-effectiveness of the combined regimen of ezetimibe and moderate-dose statins may not be promising.…”